These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34184074)

  • 1. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
    Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
    J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
    Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
    Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
    Niu L; Gao Z; Cui Y; Yang X; Li H
    Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
    Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
    Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway.
    Zhang X; He Y; Jiang Y; Bao Y; Chen Q; Xie D; Yu H; Wang X
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
    Zhou XY; Shu XM
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
    Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
    Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
    Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
    Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
    Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
    Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
    Cai W; Ni W; Jin Y; Li Y
    Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NORAD regulates epithelial‑mesenchymal transition of non‑small cell lung cancer cells via miR‑422a.
    Chen Z; Che Q; Xie C
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TPX2 Promotes Metastasis and Serves as a Marker of Poor Prognosis in Non-Small Cell Lung Cancer.
    Zhou F; Wang M; Aibaidula M; Zhang Z; Aihemaiti A; Aili R; Chen H; Dong S; Wei W; Maimaitiaili A
    Med Sci Monit; 2020 Aug; 26():e925147. PubMed ID: 32748897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion.
    Dong YZ; Meng XM; Li GS
    Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2671-2679. PubMed ID: 29771418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
    Xing Y; Meng Q; Chen X; Zhao Y; Liu W; Hu J; Xue F; Wang X; Cai L
    Oncotarget; 2016 May; 7(21):30479-91. PubMed ID: 27058415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.